Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

Catherine O'Doherty, Alexander Favorov, Shirley Heggarty, Colin Graham, Olga Favorova, Michael Ochs, Stanley Hawkins, Michael Hutchinson, Killian O'Rourke, Koen Vandenbroeck

Research output: Contribution to journalArticle

Abstract

Introduction: IFN-β is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources. Materials & methods: We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-β response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-based approach (APSampler). Results: The most significant allelic combinations, which differed in frequency between responders and nonresponders, included JAK2-IL10RB-GBP1-PIAS1 (permutation p-value was p perm = 0.0008), followed by JAK2-IL10-CASP3 (p perm = 0.001). Discussion: The genetic mechanism of response to IFN-β is complex and as yet poorly understood. Data mining algorithms may help in uncovering hidden allele combinations involved in drug response versus nonresponse.

Original languageEnglish (US)
Pages (from-to)1177-1186
Number of pages10
JournalPharmacogenomics
Volume10
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Genetic Polymorphisms
Multiple Sclerosis
Alleles
Therapeutics
Markov Chains
Data Mining
Caspase 3
Interleukin-10
Single Nucleotide Polymorphism
Early Diagnosis
Patient Care
Pharmaceutical Preparations
Genes

Keywords

  • APSampler
  • Bayesian statistics
  • IFN-β
  • Multiple sclerosis
  • Pharmacogenomics
  • Polymorphism

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients. / O'Doherty, Catherine; Favorov, Alexander; Heggarty, Shirley; Graham, Colin; Favorova, Olga; Ochs, Michael; Hawkins, Stanley; Hutchinson, Michael; O'Rourke, Killian; Vandenbroeck, Koen.

In: Pharmacogenomics, Vol. 10, No. 7, 07.2009, p. 1177-1186.

Research output: Contribution to journalArticle

O'Doherty, C, Favorov, A, Heggarty, S, Graham, C, Favorova, O, Ochs, M, Hawkins, S, Hutchinson, M, O'Rourke, K & Vandenbroeck, K 2009, 'Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients', Pharmacogenomics, vol. 10, no. 7, pp. 1177-1186. https://doi.org/10.2217/pgs.09.41
O'Doherty, Catherine ; Favorov, Alexander ; Heggarty, Shirley ; Graham, Colin ; Favorova, Olga ; Ochs, Michael ; Hawkins, Stanley ; Hutchinson, Michael ; O'Rourke, Killian ; Vandenbroeck, Koen. / Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients. In: Pharmacogenomics. 2009 ; Vol. 10, No. 7. pp. 1177-1186.
@article{f63d8ca9a50a4cc6ad37b3741025f45c,
title = "Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients",
abstract = "Introduction: IFN-β is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50{\%} of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources. Materials & methods: We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-β response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-based approach (APSampler). Results: The most significant allelic combinations, which differed in frequency between responders and nonresponders, included JAK2-IL10RB-GBP1-PIAS1 (permutation p-value was p perm = 0.0008), followed by JAK2-IL10-CASP3 (p perm = 0.001). Discussion: The genetic mechanism of response to IFN-β is complex and as yet poorly understood. Data mining algorithms may help in uncovering hidden allele combinations involved in drug response versus nonresponse.",
keywords = "APSampler, Bayesian statistics, IFN-β, Multiple sclerosis, Pharmacogenomics, Polymorphism",
author = "Catherine O'Doherty and Alexander Favorov and Shirley Heggarty and Colin Graham and Olga Favorova and Michael Ochs and Stanley Hawkins and Michael Hutchinson and Killian O'Rourke and Koen Vandenbroeck",
year = "2009",
month = "7",
doi = "10.2217/pgs.09.41",
language = "English (US)",
volume = "10",
pages = "1177--1186",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

AU - O'Doherty, Catherine

AU - Favorov, Alexander

AU - Heggarty, Shirley

AU - Graham, Colin

AU - Favorova, Olga

AU - Ochs, Michael

AU - Hawkins, Stanley

AU - Hutchinson, Michael

AU - O'Rourke, Killian

AU - Vandenbroeck, Koen

PY - 2009/7

Y1 - 2009/7

N2 - Introduction: IFN-β is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources. Materials & methods: We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-β response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-based approach (APSampler). Results: The most significant allelic combinations, which differed in frequency between responders and nonresponders, included JAK2-IL10RB-GBP1-PIAS1 (permutation p-value was p perm = 0.0008), followed by JAK2-IL10-CASP3 (p perm = 0.001). Discussion: The genetic mechanism of response to IFN-β is complex and as yet poorly understood. Data mining algorithms may help in uncovering hidden allele combinations involved in drug response versus nonresponse.

AB - Introduction: IFN-β is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources. Materials & methods: We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-β response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-based approach (APSampler). Results: The most significant allelic combinations, which differed in frequency between responders and nonresponders, included JAK2-IL10RB-GBP1-PIAS1 (permutation p-value was p perm = 0.0008), followed by JAK2-IL10-CASP3 (p perm = 0.001). Discussion: The genetic mechanism of response to IFN-β is complex and as yet poorly understood. Data mining algorithms may help in uncovering hidden allele combinations involved in drug response versus nonresponse.

KW - APSampler

KW - Bayesian statistics

KW - IFN-β

KW - Multiple sclerosis

KW - Pharmacogenomics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=70449504564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449504564&partnerID=8YFLogxK

U2 - 10.2217/pgs.09.41

DO - 10.2217/pgs.09.41

M3 - Article

VL - 10

SP - 1177

EP - 1186

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 7

ER -